<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966494</url>
  </required_header>
  <id_info>
    <org_study_id>20131004</org_study_id>
    <nct_id>NCT04966494</nct_id>
  </id_info>
  <brief_title>Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women</brief_title>
  <official_title>Effect of the Consumption of a Common Bean (Phaseolus Vulgaris L.) and Oats Snack Bar on the Proteomic Profile of Human Mononuclear Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Queretaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Queretaro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertriglyceridemia is a serious condition in the Mexican population and it is considered a&#xD;
      major risk factor for cardiovascular disease. Current efforts to prevent dyslipidemia and&#xD;
      lipids alteration include the development of functional products as an alternative for the&#xD;
      management of hypertriglyceridemia. Common beans (Phaseolus vulgaris L.) are a recognized&#xD;
      good source of bioactive compounds, mainly phenolic compounds, total dietary fiber (insoluble&#xD;
      and soluble fiber, resistant starch and oligosaccharides), saponins, and phytosterols that&#xD;
      exert hypolipidemic effects. In this sense, the development of beans-based food products is&#xD;
      an alternative for improving the general health status. In previous work, a beans-oats snack&#xD;
      bar formulation was found to be a promising potential functional product. In order to&#xD;
      validate those results, the aim of this works was to assess a clinical trial was conducted&#xD;
      with Mexican women to assess the effect of daily consumption of the functional product on&#xD;
      serum triglycerides and certain plasma proteins involved in lipids metabolism in a clinical&#xD;
      trial. The clinical trial was 2 months, randomized parallel study where 32 women with&#xD;
      elevated triglycerides were randomized into the treatment group and control group. The&#xD;
      Control group received nutritional orientation whereas the treatment group received the&#xD;
      orientation and consumed 50 g of the product per day. Fasting blood samples were collected at&#xD;
      baseline and the end of the study, obtaining serum and plasma for analysis of lipids profile,&#xD;
      glucose, and biomarkers. To determine changes in plasma proteins, a 182 protein Human Obesity&#xD;
      Antibody Array was used, and the results were analyzed using a bioinformatic-based analysis&#xD;
      from Ingenuity Pathways Analysis (QIAGEN)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2013</start_date>
  <completion_date type="Actual">November 2, 2015</completion_date>
  <primary_completion_date type="Actual">July 13, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>8 weeks</time_frame>
    <description>Significant change</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>Significant change</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>BOSB Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consumed a common beans and oats snack bar (BOSB) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group corresponded to hypertriglyceridemic women who does not consume BOSB</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BOSB</intervention_name>
    <description>BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.</description>
    <arm_group_label>BOSB Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No current diagnoses of illnesses.&#xD;
&#xD;
          -  Triglycerides levels among 150 and 350 mg/dL.&#xD;
&#xD;
          -  No allergies to common beans and oats.&#xD;
&#xD;
          -  Not pregnant or lactating.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If they had current diagnoses of diabetes, hypertension, irritable bowel syndrome, or&#xD;
             cancer.&#xD;
&#xD;
          -  Taking anti-inflammatory drugs.&#xD;
&#xD;
          -  Fasting glucose &gt;100 mg/dL, total cholesterol &gt;240 mg/dL, LDL C&gt;160 mg/dL.&#xD;
&#xD;
          -  Reported intolerances to BOSB ingredients.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guadalupe Loarca-Pi√±a, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonoma de Queretaro</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Queretaro</investigator_affiliation>
    <investigator_full_name>Ivan Luzardo-Ocampo</investigator_full_name>
    <investigator_title>Associate Researcher</investigator_title>
  </responsible_party>
  <keyword>Common beans</keyword>
  <keyword>Oats</keyword>
  <keyword>Proteomic Analysis</keyword>
  <keyword>Phenolic compounds</keyword>
  <keyword>Dietary Fiber</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available upon reasonable request</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>10 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

